At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 4 clinical trial evaluating dupilumab and Topical emollient (moisturizer) for Moderate-to-Severe Atopic Dermatitis and Atopic Eczema. Completed, enrolled 124 participants across 30 sites.
Detailed Summary
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in your blood at different times * How much the study drug improves quality of life and mental health
Study Details
Timeline
Interventions
Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.